What are ADC's

Our services

ADC Review
is made possible by:

NCT01475006 (Clinical Trial/ AMG 595)

Study Title
AMG 595 First-in-Human in Recurrent Gliomas (NCT01475006)

Trial Description
This is an open-label, sequential dose exploration study of single agent AMG 595 administered in subjects with recurrent glioblastoma multiforme (GBM) and/or anaplastic astrocytomas (AA). The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics (PK) of AMG 595, and also to evaluate the objective response rate in subjects receiving AMG 595.

This study will be conducted in two parts. Part 1 will explore doses of AMG 595 in subjects with recurrent GBM and/or AA. Part 2 (dose expansion) will examine the MTD established in Part 1 in subjects with recurrent GBM. This trial is sponsored by Amgen. [1]

Study Data

  • Condition: Recurrent Gliomas
  • Interventions:
    • Drugs used in this trial
      • AMG 595
  • Phase: I
  • Enrollment: 32
  • Start: February 2012
  • Estimated Completion: April 2016
  • Last Verified: April 2016

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: August 28, 2017
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar